(Q35101832)

6 August 2017

title

Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays (English)

1 reference

6 August 2017

Melissa McNulty

1

1 reference

6 August 2017

Ravinder J Singh

2

1 reference

6 August 2017

Xujian Li

3

1 reference

6 August 2017

Eric J Bergstralh

4

1 reference

6 August 2017

Rajiv Kumar

5

1 reference

6 August 2017

language of work or name

English

0 references

publication date

4 May 2011

1 reference

The Journal of Clinical Endocrinology and Metabolism

6 August 2017

published in

1 reference

6 August 2017

volume

96

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

E1159-62

1 reference

Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin binds and regulates the activity of cysteine-rich protein 61.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Eight genes are highly associated with BMD variation in postmenopausal Caucasian women

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135202

Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21543425

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21543425

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2011-0254

1 reference

6 August 2017

1 reference

6 August 2017

1 reference